This Week in Pediatric Oncology
Science
April 25, 2011
In this third episode, host Tim Cripe, MD, PhD, asks his co-hosts to discuss two recent papers that provide new information about genetic predisposition to increased toxicity to vincristine in some children, and the results of a phase II study using a combination therapy (irinotecan and temozolomide) in relapsed or refractory neuroblastoma.
1:24 Maureen O'Brien, MD discusses "Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia" in Pediatr Blood Cancer. 2011 Mar;56(3):361-7. doi: 10.1002/pbc.22845. Epub 2010 Nov 11.http://www.ncbi.nlm.nih.gov/pubmed/21225912
22:10 Lars Wagner, MD discusses "Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study" from J Clin Oncol. 2011 Jan 10;29(2):208-13. Epub 2010 Nov 29. http://www.ncbi.nlm.nih.gov/pubmed/21115869
TWiPO #12 ~ ALL: Anti-CD19 BiTE and Genetic Risk Groups
TWiPO #11 ~ BuMel SIOP results and MIBG transplant with Dr Brian Weiss
TWiPO #10 ~ Interview with Dr Robert Seeger
TWiPO #9 ~ Interview with Dr Peter Adamson
TWiPO #8 ~ Seneca Valley virus and medulloblastoma
TWiPO #7 ~ Interview with E. Anders Kolb and Andrew Napper on drug development
TWiPO #6 ~ Interview with Dr Archie Bleyer
TWiPO #5 ~ Hedgehog Signaling and Itraconazole
TWiPO #4 ~ Meetings Recap and Immunotherapy for Synovial Cell Sarcoma
TWiPO #2 ~ Interview with Greg Reaman
TWiPO #1 ~ Epidemiology of Childhood Cancer
Create your
podcast in
minutes
It is Free
The Psychic Elephant Radio Podcast
DNA Today: A Genetics Podcast
Museum of the Missing
Sasquatch Chronicles
Hidden Brain